Qube Research & Technologies (QRT)
TCRX icon

Qube Research & Technologies (QRT)’s TScan Therapeutics TCRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,675
Closed -$50.4K – 4074
2025
Q3 		$50.4K Sell
27,675
-40,611
-59% -$71.9K ﹤0.01% 3180
2025
Q2 		$99K Buy
+68,286
New +$98.7K ﹤0.01% 3039
2025
Q1 		– Sell
-14,508
Closed -$44.1K – 3881
2024
Q4 		$44.1K Sell
14,508
-40,056
-73% -$182K ﹤0.01% 3112
2024
Q3 		$272K Sell
54,564
-23,821
-30% -$144K ﹤0.01% 2465
2024
Q2 		$459K Sell
78,385
-65,151
-45% -$513K ﹤0.01% 2180
2024
Q1 		$1.14M Buy
143,536
+63,547
+79% +$400K ﹤0.01% 2067
2023
Q4 		$466K Buy
79,989
+77,579
+3,219% +$355K ﹤0.01% 2330
2023
Q3 		$6.17K Buy
+2,410
New +$5.62K ﹤0.01% 3410

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TCRX Position: Q4 2025 in Review

Qube Research & Technologies (QRT) sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 27,675 shares — an estimated $50.4K sold.

Qube Research & Technologies (QRT) first reported a position in TCRX in Q3 2023 and held it in 8 quarters. The position peaked at $1.14M in Q1 2024. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Qube Research & Technologies (QRT) reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 27,675 TScan Therapeutics shares in Q4 2025, an estimated $50.4K.
  • Qube Research & Technologies (QRT) first reported a position in TScan Therapeutics in Q3 2023 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s TScan Therapeutics position peaked at $1.14M in Q1 2024.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2025, filed 17 Feb 2026.